Budesonide use in pediatric crohn disease

Anthony Otley, Neal Leleiko, Christine Langton, Trudy Lerer, David MacK, Jonathan Evans, Marian Pfefferkorn, Ryan Carvalho, Joel Rosh, Anne Griffiths, Maria Oliva-Hemker, Marsha Kay, Athos Bousvaros, Michael Stephens, Charles Samson, Andrew Grossman, David Keljo, James Markowitz, Jeffrey Hyams

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND AND AIM:: Budesonide (BUD) is being used in pediatric Crohn disease (CD) because it is believed to have the potential to reduce corticosteroid-related toxicity; however, few data are available describing its use. The aim of the present study was to describe BUD use in an inception cohort of pediatric patients with CD. METHODS:: Data were derived from the prospective Pediatric IBD Collaborative Research Group Registry established in 2002 in North America. Use of BUD in children with CD was examined. RESULTS:: BUD was used in 119 of 932 (13%) of children with newly diagnosed CD, with 56 of 119 (47%) starting BUD ≤30 days of diagnosis (26/56 with ileum and/or ascending colon [IAC] disease). BUD was used as monotherapy (9%), in combination with 5-aminosalicylates (77%), or in combination with immunomodulators (43%). Forty-three percent (24/56) went on to receive conventional corticosteroid at some point following their first BUD course. For the 63 of 119 (53%) who started BUD beyond the diagnosis period, 51 of 63 (81%) also received prednisone, with BUD used as a means of weaning from prednisone in 17 of 63 (27%). Patients with IAC disease who received BUD ≤30 days of diagnosis were just as likely to have received conventional corticosteroids by 1 year as were those who did not receive BUD ≤30 days of diagnosis. Two-thirds (77/119) of patients received BUD for ≤6 months. CONCLUSIONS:: BUD is being used among pediatric patients newly diagnosed as having CD, although the majority does not have disease limited to the IAC. BUD monotherapy was rare, and further data are required to better define the role of BUD in the treatment of pediatric CD.

Original languageEnglish (US)
Pages (from-to)200-204
Number of pages5
JournalJournal of pediatric gastroenterology and nutrition
Volume55
Issue number2
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Budesonide
Ascending Colon
Crohn Disease
Ileum
Adrenal Cortex Hormones
Pediatric Crohn's disease
Pediatrics
Prednisone
Mesalamine
Immunologic Factors
North America
Weaning

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

Otley, A., Leleiko, N., Langton, C., Lerer, T., MacK, D., Evans, J., ... Hyams, J. (2012). Budesonide use in pediatric crohn disease. Journal of pediatric gastroenterology and nutrition, 55(2), 200-204. https://doi.org/10.1097/MPG.0b013e31824a09c2
Otley, Anthony ; Leleiko, Neal ; Langton, Christine ; Lerer, Trudy ; MacK, David ; Evans, Jonathan ; Pfefferkorn, Marian ; Carvalho, Ryan ; Rosh, Joel ; Griffiths, Anne ; Oliva-Hemker, Maria ; Kay, Marsha ; Bousvaros, Athos ; Stephens, Michael ; Samson, Charles ; Grossman, Andrew ; Keljo, David ; Markowitz, James ; Hyams, Jeffrey. / Budesonide use in pediatric crohn disease. In: Journal of pediatric gastroenterology and nutrition. 2012 ; Vol. 55, No. 2. pp. 200-204.
@article{5c455b95170c4f41a4ac8d01eb188e0c,
title = "Budesonide use in pediatric crohn disease",
abstract = "BACKGROUND AND AIM:: Budesonide (BUD) is being used in pediatric Crohn disease (CD) because it is believed to have the potential to reduce corticosteroid-related toxicity; however, few data are available describing its use. The aim of the present study was to describe BUD use in an inception cohort of pediatric patients with CD. METHODS:: Data were derived from the prospective Pediatric IBD Collaborative Research Group Registry established in 2002 in North America. Use of BUD in children with CD was examined. RESULTS:: BUD was used in 119 of 932 (13{\%}) of children with newly diagnosed CD, with 56 of 119 (47{\%}) starting BUD ≤30 days of diagnosis (26/56 with ileum and/or ascending colon [IAC] disease). BUD was used as monotherapy (9{\%}), in combination with 5-aminosalicylates (77{\%}), or in combination with immunomodulators (43{\%}). Forty-three percent (24/56) went on to receive conventional corticosteroid at some point following their first BUD course. For the 63 of 119 (53{\%}) who started BUD beyond the diagnosis period, 51 of 63 (81{\%}) also received prednisone, with BUD used as a means of weaning from prednisone in 17 of 63 (27{\%}). Patients with IAC disease who received BUD ≤30 days of diagnosis were just as likely to have received conventional corticosteroids by 1 year as were those who did not receive BUD ≤30 days of diagnosis. Two-thirds (77/119) of patients received BUD for ≤6 months. CONCLUSIONS:: BUD is being used among pediatric patients newly diagnosed as having CD, although the majority does not have disease limited to the IAC. BUD monotherapy was rare, and further data are required to better define the role of BUD in the treatment of pediatric CD.",
author = "Anthony Otley and Neal Leleiko and Christine Langton and Trudy Lerer and David MacK and Jonathan Evans and Marian Pfefferkorn and Ryan Carvalho and Joel Rosh and Anne Griffiths and Maria Oliva-Hemker and Marsha Kay and Athos Bousvaros and Michael Stephens and Charles Samson and Andrew Grossman and David Keljo and James Markowitz and Jeffrey Hyams",
year = "2012",
month = "8",
day = "1",
doi = "10.1097/MPG.0b013e31824a09c2",
language = "English (US)",
volume = "55",
pages = "200--204",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Otley, A, Leleiko, N, Langton, C, Lerer, T, MacK, D, Evans, J, Pfefferkorn, M, Carvalho, R, Rosh, J, Griffiths, A, Oliva-Hemker, M, Kay, M, Bousvaros, A, Stephens, M, Samson, C, Grossman, A, Keljo, D, Markowitz, J & Hyams, J 2012, 'Budesonide use in pediatric crohn disease', Journal of pediatric gastroenterology and nutrition, vol. 55, no. 2, pp. 200-204. https://doi.org/10.1097/MPG.0b013e31824a09c2

Budesonide use in pediatric crohn disease. / Otley, Anthony; Leleiko, Neal; Langton, Christine; Lerer, Trudy; MacK, David; Evans, Jonathan; Pfefferkorn, Marian; Carvalho, Ryan; Rosh, Joel; Griffiths, Anne; Oliva-Hemker, Maria; Kay, Marsha; Bousvaros, Athos; Stephens, Michael; Samson, Charles; Grossman, Andrew; Keljo, David; Markowitz, James; Hyams, Jeffrey.

In: Journal of pediatric gastroenterology and nutrition, Vol. 55, No. 2, 01.08.2012, p. 200-204.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Budesonide use in pediatric crohn disease

AU - Otley, Anthony

AU - Leleiko, Neal

AU - Langton, Christine

AU - Lerer, Trudy

AU - MacK, David

AU - Evans, Jonathan

AU - Pfefferkorn, Marian

AU - Carvalho, Ryan

AU - Rosh, Joel

AU - Griffiths, Anne

AU - Oliva-Hemker, Maria

AU - Kay, Marsha

AU - Bousvaros, Athos

AU - Stephens, Michael

AU - Samson, Charles

AU - Grossman, Andrew

AU - Keljo, David

AU - Markowitz, James

AU - Hyams, Jeffrey

PY - 2012/8/1

Y1 - 2012/8/1

N2 - BACKGROUND AND AIM:: Budesonide (BUD) is being used in pediatric Crohn disease (CD) because it is believed to have the potential to reduce corticosteroid-related toxicity; however, few data are available describing its use. The aim of the present study was to describe BUD use in an inception cohort of pediatric patients with CD. METHODS:: Data were derived from the prospective Pediatric IBD Collaborative Research Group Registry established in 2002 in North America. Use of BUD in children with CD was examined. RESULTS:: BUD was used in 119 of 932 (13%) of children with newly diagnosed CD, with 56 of 119 (47%) starting BUD ≤30 days of diagnosis (26/56 with ileum and/or ascending colon [IAC] disease). BUD was used as monotherapy (9%), in combination with 5-aminosalicylates (77%), or in combination with immunomodulators (43%). Forty-three percent (24/56) went on to receive conventional corticosteroid at some point following their first BUD course. For the 63 of 119 (53%) who started BUD beyond the diagnosis period, 51 of 63 (81%) also received prednisone, with BUD used as a means of weaning from prednisone in 17 of 63 (27%). Patients with IAC disease who received BUD ≤30 days of diagnosis were just as likely to have received conventional corticosteroids by 1 year as were those who did not receive BUD ≤30 days of diagnosis. Two-thirds (77/119) of patients received BUD for ≤6 months. CONCLUSIONS:: BUD is being used among pediatric patients newly diagnosed as having CD, although the majority does not have disease limited to the IAC. BUD monotherapy was rare, and further data are required to better define the role of BUD in the treatment of pediatric CD.

AB - BACKGROUND AND AIM:: Budesonide (BUD) is being used in pediatric Crohn disease (CD) because it is believed to have the potential to reduce corticosteroid-related toxicity; however, few data are available describing its use. The aim of the present study was to describe BUD use in an inception cohort of pediatric patients with CD. METHODS:: Data were derived from the prospective Pediatric IBD Collaborative Research Group Registry established in 2002 in North America. Use of BUD in children with CD was examined. RESULTS:: BUD was used in 119 of 932 (13%) of children with newly diagnosed CD, with 56 of 119 (47%) starting BUD ≤30 days of diagnosis (26/56 with ileum and/or ascending colon [IAC] disease). BUD was used as monotherapy (9%), in combination with 5-aminosalicylates (77%), or in combination with immunomodulators (43%). Forty-three percent (24/56) went on to receive conventional corticosteroid at some point following their first BUD course. For the 63 of 119 (53%) who started BUD beyond the diagnosis period, 51 of 63 (81%) also received prednisone, with BUD used as a means of weaning from prednisone in 17 of 63 (27%). Patients with IAC disease who received BUD ≤30 days of diagnosis were just as likely to have received conventional corticosteroids by 1 year as were those who did not receive BUD ≤30 days of diagnosis. Two-thirds (77/119) of patients received BUD for ≤6 months. CONCLUSIONS:: BUD is being used among pediatric patients newly diagnosed as having CD, although the majority does not have disease limited to the IAC. BUD monotherapy was rare, and further data are required to better define the role of BUD in the treatment of pediatric CD.

UR - http://www.scopus.com/inward/record.url?scp=84863852359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863852359&partnerID=8YFLogxK

U2 - 10.1097/MPG.0b013e31824a09c2

DO - 10.1097/MPG.0b013e31824a09c2

M3 - Article

C2 - 22258289

AN - SCOPUS:84863852359

VL - 55

SP - 200

EP - 204

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 2

ER -

Otley A, Leleiko N, Langton C, Lerer T, MacK D, Evans J et al. Budesonide use in pediatric crohn disease. Journal of pediatric gastroenterology and nutrition. 2012 Aug 1;55(2):200-204. https://doi.org/10.1097/MPG.0b013e31824a09c2